formal address impact view januari guidanc
stale lower number reflect estim disrupt
pandem larger-than-expect fx impact year
oper resili large-cap name hardest
hit non-diabet medic devic core diagnost
show stabil apart non-diabet devic diagnost
report result april compani issu guidanc januari
time project organ sale growth around ep
worsen pandem sinc januari made compani
target outdat along full-year guidanc metric provid concurr
gener speak regard two four divis fairli resili epd solid
global pharmaci script trend help accommod impact elsewher
divis nutrit address mostli essenti need show strength
product like pedialyt diagnost expos slowdown
less frequent routin test monthli test drug monitor well test
caus soft core lab segment diagnost like get partial off-set flu
volum molecular test medic devic segment similarli mix reflect
sizabl elect procedur risk area like cardio neuromodul diabet product
partial buffer softer medic devic result sale select area like heart
failur procedur larg non-elect
weve revis estim greater-than-expect fx impact
expect neg affect quarter year hardest-
hit period also updat forecast currenc chang sinc januari
dollar strengthen consider year date particularli march
pandem intensifi signific portion revenu gener non-usd
currenc total sale gener outsid last year
compani project neg currenc impact report sale littl
neg impact full year headwind nearli
bp wors bp wors year model
organ sale growth report sale growth declin ep
prior estim respect
project organ sale growth declin report sale growth declin
ep context origin guid organ sale
growth ep previou project
respect complet revis estim shown figur page
suspect follow rout taken nearli everi medic devic compani
withdraw full-year guidanc due uncertainti tie still
rel better oper resili large-cap name
cover pandem subsid compani see reliabl sale growth
multipl product driver report thursday give us opportun
refin latest assumpt regard near-term neg impact currenc
pleas see page report import disclosur
spin-out proprietari pharma new redux pre-humira
larg diversifi medic product compani competit global franchis
nutrit diagnost medic devic intern brand gener pharmaceut
post-spin ad st jude medic aler busi divest
advanc medic optic unit next five year believ combin abt/stj/
alr busi pois deliv revenu growth ep growth
low mid-teen make standout perform compar medic devic peer
believ may upsid estim potenti out-performance busi
unit better-than-expect contribut stj pipelin product success
business-develop initi blend valuat analysi dcf sum-of-the-part
price-to-earnings support outperform rate expect share outperform market
next month
fda approv libr
decis libr
increas market adopt mitraclip
 roll-out alin
gross oper margin expans
next five year
 enhanc product
acceler diagnost unit
stronger stj synergi captur alr
acceler recoveri intern
hsd revenu mid-dd ep growth
persist emerg market headwind
nutrit
franchis four major health care segment one diversifi
large-cap medic devic compani world offer lead product
nutrit diagnost medic devic establish brand gener pharmaceut
approxim compani revenu gener unit state
anoth come western europ canada japan australia remain
emerg market includ india china russia brazil januari
complet separ proprietari research-bas pharmaceut busi
oper independ large-cap pharmaceut compani
compani report thomson eikon cowen compani
good gross gross margin oper interest interest net interest expens currenc hedg expens net expens pre-tax incom tax incom tax net incom continu restructur non-recur charg net incom continu oper restructur non-recur charg dilut share analysisgross end decemb end decemb end decemb cowen
compani report thomson eikon cowen compani
laboratori diagnost laboratori diagnost molecular diagnost point diagnost point diabet revenu rhythm manag heart failur rhythm manag heart cardiovascular structur heart cardiovascular structur revenu end decemb end decemb end decemb cowen
compani report thomson eikon cowen compani
adjust good adjust gross adjust gross oper incom oper incom interest expens interest net interest expens currenc hedg loss expens net expens pre-tax incom incom tax incom tax net incom adj net incom oper net incom oper ep continu oper ep discontinu oper changeadjust ep oper includ disc ep oper share analysisgross incom -oper cowen
compani report thomson eikon cowen compani
 exclud ww sale exclud pharma exclud exclud ww sale exclud devic rhythm manag heart failur exclud ww rhythm manag heart ww sale exclud cardiovascular structur heart exclud ww ww sale exclud neuromodul exclud ww ww sale exclud neuromodul exclud ww stj ww sale exclud diabet exclud ww diabet ww sale exclud devic exclud ww medic ww sale exclud revenu exclud ww ww sale exclud total revenu exclud ww sale exclud total revenu pro-forma stj alr exclud ww sale exclud cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
risk includ stj alr integr global competit pressur adult
pediatr nutrit busi price pressur procedur volum pressur
stent busi vascular product regulatori time approv mitraclip
 risk time regulatori approv meet demand
hundr product launch emerg market establish pharmaceut
busi meet growth target develop emerg market
meet target margin improv four major segment
